Skip navigation

Critical Updates on Pressing Issues Including Drug Pricing Oversight, Value-Based Frameworks and State Pricing Transparency

November 7-8, 2018
  • Location, TBD

Bio/pharma manufacturers continue to grapple with a rapidly evolving healthcare landscape and heavy government scrutiny and oversight on price reporting. With the advent of Trump’s America First Blueprint, the outlook is that the scrutiny will continue and pressures to curb drug costs will rise. CBI’s Government Pricing and Reporting Forum provides and in-depth look at potential areas of reform and offer operational strategies around value-based frameworks, state pricing requirements, 340B and commercial contracting.

Benefit From Operational Strategies and Discussion on Topics Including:

  • Regulatory Changes and Price Reporting Implications
  • Legislation Impacting Medicaid Drug Spending and Expansion
  • 340B Analytics and Duplicate Discount Prevention
  • State Pricing Transparency Requirements
  • Commercial Contracting and Price Protection
  • Value-Based Contracting and Government Pricing Considerations
  • FCP Pricing and Requirements
  • Generic Inflation Penalty and Baseline AMP Calculations
  • Documentation and Reasonable Assumptions

Attendee Acclaim From CBI’s Government Pricing Series:

The conference was informative and a great opportunity to network with industry peers.

Excellent conference with best in class speakers!

Very informative, good discussion, great networking!

The content was great.

Excellent content and subject matter experts along with great networking and benchmarking opportunities for networking.

Up to the minute updates, informative and great speakers.

Government Pricing and Reporting Forum

Critical Updates on Pressing Issues Including Drug Pricing Oversight, Value-Based Frameworks and State Pricing Transparency

Bio/pharma manufacturers continue to grapple with a rapidly evolving healthcare landscape and heavy government scrutiny and oversight on price reporting. With the advent of Trump’s America First Blueprint, the outlook is that the scrutiny will continue and pressures to curb drug costs will rise. CBI’s Government Pricing and Reporting Forum provides and in-depth look at potential areas of reform and offer operational strategies around value-based frameworks, state pricing requirements, 340B and commercial contracting.

Benefit From Operational Strategies and Discussion on Topics Including:

  • Regulatory Changes and Price Reporting Implications
  • Legislation Impacting Medicaid Drug Spending and Expansion
  • 340B Analytics and Duplicate Discount Prevention
  • State Pricing Transparency Requirements
  • Commercial Contracting and Price Protection
  • Value-Based Contracting and Government Pricing Considerations
  • FCP Pricing and Requirements
  • Generic Inflation Penalty and Baseline AMP Calculations
  • Documentation and Reasonable Assumptions

Attendee Acclaim From CBI’s Government Pricing Series:

The conference was informative and a great opportunity to network with industry peers.

Excellent conference with best in class speakers!

Very informative, good discussion, great networking!

The content was great.

Excellent content and subject matter experts along with great networking and benchmarking opportunities for networking.

Up to the minute updates, informative and great speakers.